Back to News
Market Impact: 0.25
Hemab Doses First Participant In Phase 1 HMB-003 Trial For Heavy Menstrual Bleeding
Source: Nasdaq
Healthcare & BiotechProduct Launches
Hemab Therapeutics (COAG) dosed the first participant in its Phase 1 trial of HMB-003, an investigational peptide therapy for heavy bleeding associated with blood coagulation disorders. The milestone advances the company’s clinical-stage pipeline, though efficacy and safety data remain pending.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
COAG0.45
More News
- Waymo to launch robotaxis in Singapore, its first Southeast Asia market, by 2028
- Waymo to bring autonomous ride-hailing to Singapore in 2028
- Halozyme prices $1.3 billion convertible notes offering
- Waymo says Singapore will be its next international robotaxi city
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A